Objective: To investigate the effect of preoperative serum thyroglobulin(TG) and calcitonin(CT) on the prognosis of recurrent thyroid cancer treated with microwave ablation. Methods: Totally 112 patients with recurrent thyroid cancer who underwent microwave ablation in Shanghai Hudong Hospital were involved and followed up. Preoperative and follow-up data of survival group and death group were compared, and the effect of TG and CT levels before microwave ablation on the postoperative survival rate of patients with recurrent thyroid cancer was analyzed. Results: Preoperative serum TG, CT, diameter of recurrent lesion, galectin-3, and vascular endothelial growth factor were significantly higher in the death group than those in the survival group(P<0.05). Preoperative serum TG(HR=2.832, 95%CI:3.691-13.263, P=0.012), CT(HR=2.443, 95%CI:1.565-7.902, P=0.028) was closely related to survival after microwave ablation of recurrent thyroid cancer and was an independent prognostic factor. The 1-, 2- and 5- year cumulative survival rates of patients with normal preoperative serum TG(<60 μg·L-1) and abnormal levels(≥ 60 μg·L-1) were 0.904, 0.826, 0.317 and 0.783, 0.543, 0.194, respectively. The 1-, 2- and 5- year cumulative survival rates of patients with normal CT(<100 ng·L-1) and abnormal CT levels(≥ 100 ng·L-1) were 0.875, 0.738, 0.336 and 0.812, 0.558, 0.169, respectively. All the differences were statistically significant(P<0.05). Conclusion: The levels of serum TG and CT before microwave ablation in patients with recurrent thyroid cancer have some predictive value in the prognosis, and it is of clinical significance to control the two indexes for long-term survival of patients with recurrent thyroid cancer. |
[1] 杨雷,王宁.甲状腺癌流行病学研究进展[J].中华预防医学杂志,2014,48(8):744-748.
[2] 王龙琦,陈坚,刘绪舜.微波消融术与传统开放手术在良性甲状腺结节治疗中对机体创伤影响的比较[J].中国微创外科杂志,2016,16(3):236-240.
[3] 刘玉辉,孙均,王松涛,等.老年人甲状腺结节手术切除和微波消融临床疗效和安全性对比分析[J].介入放射学杂志,2016,25(1):44-47.
[4] 只璟泰,郑向前,高明.甲状腺癌相关基因研究进展[J].中华耳鼻咽喉头颈外科杂志,2016,51(12):951-955.
[5] 田文,郗洪庆.甲状腺癌病人生存现状分析[J].中国实用外科杂志,2016,36(5):489-493.
[6] 徐景竹,王兴华,吴琼,等.颈部超声、甲状腺球蛋白诊断复发分化型甲状腺癌[J].中国癌症杂志,2016,26(1):97-101.
[7] 李晓曦.实验室检查在甲状腺结节诊治中的合理选择与评价[J].中国实用外科杂志,2015,35(6):629-633.
[8] 于守君,岳雯雯,王丹丹,等.超声引导下经皮微波消融治疗局部复发性甲状腺乳头状癌临床观察[J].山东医药,2017,57(28):62-64.
[9] 林岩松,张彬,梁智勇,等.复发转移性分化型甲状腺癌诊治共识[J].中国癌症杂志,2015,25(7):481-496.
[10] TORJAN H, KATRIN B, LARS R, et al.F18-FDG-PET for recurrent differentiated thyroid cancer:a systematic meta-analysis[J].Acta Radiologica,2016,57(10):1193-1200.
[11] SALARI B,REN Y,KAMANI D,et al.Revision neural monitored surgery for recurrent thyroid cancer:safety and thyroglobulin response[J].Laryngoscope,2015,126(4):1020-1025.
[12] 周元,蒋红钢,李克.甲状腺癌分子标志物研究进展[J].临床与实验病理学杂志,2015,31(5):565-568.
[13] 王奕平,周家华.钙结合蛋白S100A13与肿瘤关系的研究进展[J].东南大学学报:医学版,2017,36(4):670-673.
[14] FUZIO P,NAPOLI A,CIAMPOLILLO A,et al.Clusterin transcript variants expression in thyroid tumor:a potential marker of malignancy?[J].Bmc Cancer,2015,15(1):349.
[15] 黄仲杰,彭伟炜,谭介恒.210例甲状腺癌临床病理特征及预后分析[J].中国肿瘤临床与康复,2015(4):444-446. |